CD7UCAR

CD7UCAR is an investigational universal chimeric antigen receptor T-cell (CAR-T) therapy designed to treat CD7-positive malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. Developed using healthy donor T cells, the therapy employs CRISPR/Cas9 gene editing to disrupt the T-cell receptor alpha constant (TRAC) locus, thereby reducing the risk of graft-versus-host disease (GvHD), and the CD7 locus to prevent fratricide among the CAR-T cells. The CAR construct features a second-generation design with a single-chain variable fragment (scFv) derived from the HIT7 monoclonal antibody clone. Preclinical and early clinical data indicate that CD7UCAR can effectively target and eliminate CD7+ tumor cells while maintaining a favorable safety profile through the avoidance of GvHD.